Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
67.22
-2.41 (-3.46%)
At close: Nov 6, 2025, 4:00 PM EST
66.75
-0.47 (-0.70%)
After-hours: Nov 6, 2025, 5:13 PM EST
Exact Sciences Employees
Exact Sciences had 7,000 employees as of December 31, 2024. The number of employees increased by 400 or 6.06% compared to the previous year.
Employees
7,000
Change (1Y)
400
Growth (1Y)
6.06%
Revenue / Employee
$440,290
Profits / Employee
-$140,940
Market Cap
12.74B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7,000 | 400 | 6.06% |
| Dec 31, 2023 | 6,600 | 200 | 3.13% |
| Dec 31, 2022 | 6,400 | -100 | -1.54% |
| Dec 31, 2021 | 6,500 | 1,500 | 30.00% |
| Dec 31, 2020 | 5,000 | 890 | 21.65% |
| Dec 31, 2019 | 4,110 | 2,133 | 107.89% |
| Dec 31, 2018 | 1,977 | 709 | 55.91% |
| Dec 31, 2017 | 1,268 | 532 | 72.28% |
| Dec 31, 2016 | 736 | 59 | 8.71% |
| Dec 31, 2015 | 677 | 441 | 186.86% |
| Dec 31, 2014 | 236 | 134 | 131.37% |
| Dec 31, 2013 | 102 | 15 | 17.24% |
| Dec 31, 2012 | 87 | 26 | 42.62% |
| Dec 31, 2011 | 61 | 26 | 74.29% |
| Dec 31, 2010 | 35 | 16 | 84.21% |
| Dec 31, 2009 | 19 | 15 | 375.00% |
| Dec 31, 2008 | 4 | -10 | -71.43% |
| Dec 31, 2007 | 14 | -8 | -36.36% |
| Dec 31, 2006 | 22 | -27 | -55.10% |
| Dec 31, 2005 | 49 | -22 | -30.99% |
| Dec 31, 2004 | 71 | -11 | -13.41% |
| Dec 31, 2003 | 82 | 7 | 9.33% |
| Dec 31, 2002 | 75 | 7 | 10.29% |
| Dec 31, 2001 | 68 | 24 | 54.55% |
| Dec 31, 2000 | 44 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EXAS News
- 2 days ago - These Analysts Raise Their Forecasts On Exact Sciences Following Better-Than-Expected Q3 Results - Benzinga
- 2 days ago - Exact Sciences to Participate in November Investor Conference - Business Wire
- 2 days ago - Exact Sciences Corporation (EXAS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Exact Sciences Announces Third Quarter 2025 Results - Business Wire
- 10 days ago - Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps - Business Wire
- 4 weeks ago - Exact Sciences Schedules Third Quarter 2025 Earnings Call - Business Wire
- 4 weeks ago - New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies - Business Wire
- 6 weeks ago - Exact Sciences' Clear Expansion Path: Why Choose To Buy - Seeking Alpha